PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 25, 2026Kidney Diseases0 citationsOpen Access

Risk Factors for Pulmonary Hypertension and survival in Hemodialysis Patients: Are We Overlooking Serum Magnesium?

View Full Paper
JSJinhui SongXBXueqin BianBZBing Zhuang

Key Points

  • This research aims to identify the role of serum magnesium as a risk factor for pulmonary hypertension in patients undergoing hemodialysis.
  • Single-center retrospective study involving 1,077 maintenance hemodialysis patients.
  • Pulmonary hypertension diagnosed using echocardiography, with clinical data collected for analysis.
  • Nonlinear regression analysis was employed to evaluate the relationship between serum magnesium levels and pulmonary hypertension.
  • The prevalence of pulmonary hypertension was found to be 33.8% among the studied patients.
  • Patients with serum magnesium levels below 0.98 mmol/L faced a significantly higher risk of developing pulmonary hypertension.
  • Hypomagnesemia was associated with a 65% increase in mortality risk among non-pulmonary hypertension patients and an 89% increase in those with pulmonary hypertension.

Abstract

Introduction: Pulmonary hypertension (PH) is a major complication in patients undergoing maintenance hemodialysis (MHD), significantly elevating the risk of cardiovascular events and mortality, and severely impairing quality of life. Methods: In this single-center retrospective study, 1,077 MHD patients were enrolled. PH was diagnosed via echocardiography, and relevant clinical data were collected. Results: The prevalence of PH was 33.8% (364 cases). Nonlinear regression analysis indicated a significant inverse correlation between serum magnesium levels and PH. Notably, the risk of PH increased substantially when serum magnesium fell below 0.98 mmol/L. After adjusting for confounders (age, hemoglobin, serum phosphorus, NT-proBNP, left ventricular ejection fraction, extracellular water ratio, and pleural effusion), patients in the high-magnesium group (≥0.98 mmol/L) exhibited a 49.9% lower risk of PH (P=0.026). Survival analysis further confirmed that hypomagnesemia was associated with a 65% and 89% increase in mortality risk among non-PH and PH patients, respectively. Conclusion: This study provides the evidence that hypomagnesemia is an independent risk factor for PH in MHD patients and is closely associated with adverse clinical outcomes. Management of hypomagnesemia is particularly crucial in MHD patients with PH.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Song et al. (2026) studied this question.

synapsesocial.com/papers/6a13e7cf0e02ee3982d327cahttps://doi.org/10.1159/000552656
Ask AI
Helpful
Bookmark
Share
View Full Paper